[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633571":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":38,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":83,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University of Manitoba","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL",null,[13],"Drug: Levofloxacin",{"label":15,"type":16,"description":11,"interventionNames":17},"Control group","ACTIVE_COMPARATOR",[18],"Other: Usual Care",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Levofloxacin","This group will receive Levofloxacin 500mg orally daily over the 90-day trial period. Patients will take the levofloxacin daily regardless of their neutrophil count.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Usual Care","This group will receive usual care. Routine antibiotic prophylaxis is not permitted.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Brett Houston, MD, PhD","CONTACT","204-787-8552","bhouston@cancercare.mb.ca",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":37},"Nora Choi, MSc","nchoi@hsc.mb.ca",[39],{"facility":40,"status":11,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"CancerCare Manitoba","Winnipeg","Manitoba","R3E 0V9","Canada","CA",{"type":47,"coordinates":48},"Point",[49,50],-97.14704,49.8844,{"lat":50,"lon":49},[53],{"name":31,"role":32,"phone":54,"phoneExt":11,"email":34},"204-787-1103",{"type":56,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633571","phase-2-evaluation-of-antibiotic-prophylaxis-in-myelodysplastic-syndromes-and-acute-myeloid-leukemia-myelo-canabx-100633571",false,"NCT07528417","Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)","Evaluation of Antibiotic Prophylaxis Among Outpatients With Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Multicenter Pilot Trial","MYELO-CAN:ABX","Inclusion Criteria:\n\nMaster platform inclusion criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of myelodysplastic syndrome, myelodysplastic\u002Fmyeloproliferative neoplasm, or acute myeloid leukemia\n\nMYELO-CAN ABX inclusion criteria:\n\n1\\. Initiation of hypomethylating agent-based chemotherapy\n\nExclusion Criteria:\n\nMaster platform exclusion criteria:\n\n1. Participant is deemed unlikely to survive \\>30 days (as determined by clinical team)\n2. Participant unable to provide informed consent\n\nMYELO-CAN ABX exclusion criteria:\n\n1. Fever\u002Finfection within 1 month of chemotherapy initiation\n2. C-difficile infection within 12 months of chemotherapy initiation\n3. Known sensitivity\u002Fallergy to fluoroquinolones\n4. History of tendon disorders related to fluoroquinolone administration\n5. Seizure disorder\n6. Myasthenia gravis\n7. Pregnancy and\u002For breastfeeding","ALL","18 Years",{"count":68,"type":69},75,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and\u002For severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).",[75,76,77],"Myeldysplastic Syndrome (MDS)","MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)","Acute Myeloid Leukemia",[22,79,80,81,77,82],"Randomized Controlled Trial","Myelodysplastic Syndrome","Myeloproliferative Neoplasm","Neutropenia","NOT_YET_RECRUITING","2026-06-24",{"date":86,"type":87},"2026-06-29","ACTUAL",{"date":89,"type":69},"2026-09-01",{"date":91,"type":69},"2028-04-30",{"name":5,"class":6},1]